Intellia Therapeutics, Inc. (NTLA) has released encouraging Phase 2 data from its ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema (HAE). The CRISPR-based gene editing therapy showed significant reductions in attack rates, with a complete response observed in a significant number of patients. This positive news led Intellia to select 50mg as the dose for its pivotal Phase 3 study, indicating a promising outlook for the potential one-time treatment.